Recently, Jiangsu Aidea Pharmaceutical Co., Ltd. (referred to as Aidea Pharma) signed a "Licensing & Cooperation Agreement" with Kainos Medicine Inc. (284620.KS). Both parties reached an agreement on licensing for the commercial development and marketing of the innovative anti-HIV/AIDS drugs Ainuovirine tablet (ACC007) and its fixed-dose combination Ainuomiti tablet (ACC008) worldwide (excluding Mainland China, Hong Kong, Taiwan and South Korea, hereinafter referred to as "overseas"), as well as the sharing of rights and interests.

According to the agreement, Aidea Pharma will obtain the exclusive rights for overseas commercial development and marketing of Ainuovirine tablet and Ainuomiti tablet. Aidea Pharma can carry out its own research, development, production and sales within the agreed area, and has the right to sublicense all or any part of the rights granted by the agreement to any third party. Kainos Medicine will also provide reasonable commercial support and assistance for Aidea Pharma when it is applicable.

Kainos Medicine is a listed company in South Korea, specializing in the research and development of innovative drugs for the treatment of brain diseases, cancer and infectious diseases and engaged in the early development of new drugs. Aidea Pharma has reached a long-term strategic partnership with Kainos Medicine, which is the patent licensor of ACC007 in China (including mainland China, Hong Kong and Taiwan). On the basis of Aidea Pharma' two new class 1 anti-HIV/AIDS drugs being approved one after another and the steady commercialization in China, both parties intend to have further cooperation on a global scale.

Ainuovirine tablet is a new generation of non-nucleoside reverse transcriptase inhibitors. It was approved in China in June 2021 and was included in the List for National Basic Medical Insurance in December of the same year. Ainuomiti tablet was approved on December 30^th, 2022, which is the first new Class 1 triple compound single-tablet anti-HIV/AIDS drug with independent intellectual property rights in China. The approval of Ainuomiti tablet has filled the gap in the field of domestic innovative single-tablet compound formulations, providing HIV-infected patients in China a new alternative in line with international treatment regimen, as well as meeting the growing needs of diagnosis and treatment.

The signing of the "Licensing & Cooperation Agreement" is vital for Aidea Pharma to accelerate the overseas commercialization of the innovative anti-HIV/AIDS products. Dr. Heliang Fu, the chairman of Aidea Pharma, pointed out that: "Aidea Pharma and Kainos Medicine have reached a consensus on the overseas marketing of anti-HIV/AIDS innovative products toward mutual benefit. Aidea Pharma will accelerate the overseas commercialization of anti-HIV/AIDS innovative products and continue to develop series of new anti-HIV/AIDS products, so as to benefit more global HIV-infected individuals, and contribute to building a community with a shared future for mankind."